133 related articles for article (PubMed ID: 37431617)
1. The role of immune subtyping in glioma mRNA vaccine development.
Guterres A; Abrahim M; da Costa Neves PC
Immunotherapy; 2023 Sep; 15(13):1057-1072. PubMed ID: 37431617
[TBL] [Abstract][Full Text] [Related]
2. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
Front Immunol; 2021; 12():738435. PubMed ID: 34603319
[TBL] [Abstract][Full Text] [Related]
3. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
Front Immunol; 2021; 12():709986. PubMed ID: 34512630
[TBL] [Abstract][Full Text] [Related]
4. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
Front Immunol; 2022; 13():773264. PubMed ID: 35185876
[TBL] [Abstract][Full Text] [Related]
5. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
6. Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development.
Chen Z; Wang X; Yan Z; Zhang M
Cancer Med; 2022 Jul; 11(13):2711-2726. PubMed ID: 35285582
[TBL] [Abstract][Full Text] [Related]
7. Dissection of tumor antigens and immune landscape in clear cell renal cell carcinoma: Preconditions for development and precision medicine of mRNA vaccine.
Hu J; Mo Z
Math Biosci Eng; 2023 Jan; 20(2):2157-2182. PubMed ID: 36899527
[TBL] [Abstract][Full Text] [Related]
8. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
Huang X; Tang T; Zhang G; Liang T
Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination.
You W; Ouyang J; Cai Z; Chen Y; Wu X
Front Immunol; 2022; 13():827506. PubMed ID: 35874675
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell vaccines and immunity in glioma patients.
Wheeler CJ; Black KL
Front Biosci; 2005 Sep; 10():2861-81. PubMed ID: 15970541
[TBL] [Abstract][Full Text] [Related]
11. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
12. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
13. Identification of tumor-associated antigens and immune subtypes of lower-grade glioma and glioblastoma for mRNA vaccine development.
Wang ZL; Huang RY; Han B; Wu F; Sun ZY; Li GZ; Zhang W; Zhao Z; Liu X
Chin Neurosurg J; 2022 Oct; 8(1):34. PubMed ID: 36307882
[TBL] [Abstract][Full Text] [Related]
14. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development.
Wu C; Qin C; Long W; Wang X; Xiao K; Liu Q
J Big Data; 2022; 9(1):92. PubMed ID: 35855914
[TBL] [Abstract][Full Text] [Related]
15. Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine.
Ping H; Yu W; Gong X; Tong X; Lin C; Chen Z; Cai C; Guo K; Ke H
Invest New Drugs; 2022 Dec; 40(6):1173-1184. PubMed ID: 35962880
[TBL] [Abstract][Full Text] [Related]
16. Vaccines for glioblastoma and high-grade glioma.
Wheeler CJ; Black KL
Expert Rev Vaccines; 2011 Jun; 10(6):875-86. PubMed ID: 21692706
[TBL] [Abstract][Full Text] [Related]
17. Identifying tumor antigens and immuno-subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine.
Tan H; Yu T; Liu C; Wang Y; Jing F; Ding Z; Liu J; Shi H
Cancer Med; 2022 Dec; 11(23):4656-4672. PubMed ID: 35593226
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapeutic strategies for malignant glioma.
Fenstermaker RA; Ciesielski MJ
Cancer Control; 2004; 11(3):181-91. PubMed ID: 15153842
[TBL] [Abstract][Full Text] [Related]
19. Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators.
Segura-Collar B; Hiller-Vallina S; de Dios O; Caamaño-Moreno M; Mondejar-Ruescas L; Sepulveda-Sanchez JM; Gargini R
Acta Neuropathol Commun; 2023 May; 11(1):79. PubMed ID: 37165457
[TBL] [Abstract][Full Text] [Related]
20. Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development.
Chen X; Zhang T; Zhai X; Wan Z; Ge M; Liu C; Tan M; Xu D
Front Immunol; 2022; 13():1037808. PubMed ID: 36405755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
